As new biomarkers and techniques are emerging, such as α-synuclein seeding amplification assays,8,112,113 PET-tracers,114 and tissue-sensitive MRI approaches such as quantitative susceptibility mapping,82,83,115 we are optimistic that data-driven subtyping methods can eventually be combined with the right data to contribute useful insights in Parkinson’s disease prognosis and for aiding the search for disease modifying treatments.116. This evidence concerns the gene SNCA and Parkinson disease.